Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis Starts US Trial of PD-L1 as AIDS/HIV-1 Cure

publication date: May 11, 2022

Ascletis Pharma of Hangzhou was approved to start US trials of its in-licensed PD-L1 as an immune restoration/functional cure of AIDS (HIV-1). ASC22 will be administered to HIV-infected patients who are already receiving antiretroviral therapy. The Phase I/II trial will: (1) evaluate the safety of ASC22 (2) determine whether ASC22 1.0 mg/kg, given once every four weeks, improves HIV-1-specific cellular immune responses; and (3) evaluate the effects of ASC22 versus placebo on latency reversal of HIV. Ascletis in-licensed the PD-L1 from Alphamab for viral indications. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China